AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

Click here to view online. Add this email to your safelist.

8 November 2017

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.